Literature DB >> 7704028

A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer.

T Kobayashi1, Y Hirayama, E Kobayashi, Y Kubo, O Hino.   

Abstract

The Eker rat hereditary renal carcinoma (RC) is an excellent example of a mendelian dominant predisposition to a specific cancer in an experimental animal. We have previously established a new conserved linkage group on rat chromosome 10q and human chromosome 16p13.3, and shown that the Eker mutation is tightly linked to the tuberous sclerosis (Tsc2) gene. We now describe a germline mutation in the gene encoding Tsc2 caused by the insertion of an approximately 5 kilobase DNA fragment in the Eker rat, resulting in aberrant RNA expression from the mutant allele. The phenotype of tuberous sclerosis in humans differs from that of the Eker rat, except for the occurrence of renal tumours. The Eker rat may therefore provide insights into species-specific differences in tumourigenesis and/or phenotype-specific mutations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704028     DOI: 10.1038/ng0195-70

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  77 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Chromosomal localization of rat hepatocyte growth factor (Hgf) and HGF receptor (Met) and characterization of HGF receptor cDNA.

Authors:  V R Wallenius; H Rawet; S Skrtic; K Helou; Y Qiu; G Levan; S Ekberg; B Carlsson; O G Isaksson; T Nakamura; J O Jansson
Journal:  Mamm Genome       Date:  1997-09       Impact factor: 2.957

3.  Cdc6 protein obstructs apoptosome assembly and consequent cell death by forming stable complexes with activated Apaf-1 molecules.

Authors:  Shinichiro Niimi; Shiho Arakawa-Takeuchi; Baasanjav Uranbileg; Jun-ha Park; Shigeki Jinno; Hiroto Okayama
Journal:  J Biol Chem       Date:  2012-04-06       Impact factor: 5.157

4.  Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog.

Authors:  T Kobayashi; S Urakami; J P Cheadle; R Aspinwall; P Harris; J R Sampson; O Hino
Journal:  Mamm Genome       Date:  1997-08       Impact factor: 2.957

5.  A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice.

Authors:  T Kobayashi; O Minowa; Y Sugitani; S Takai; H Mitani; E Kobayashi; T Noda; O Hino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

6.  ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.

Authors:  Jennifer D Cohen; Jaime M C Gard; Raymond B Nagle; Justin D Dietrich; Terrence J Monks; Serrine S Lau
Journal:  Toxicol Sci       Date:  2011-08-02       Impact factor: 4.849

7.  Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.

Authors:  G Rennebeck; E V Kleymenova; R Anderson; R S Yeung; K Artzt; C L Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

8.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

9.  Expression and differential splicing of the mouse TSC2 homolog.

Authors:  P G Olsson; J N Schofield; Y H Edwards; A M Frischauf
Journal:  Mamm Genome       Date:  1996-03       Impact factor: 2.957

Review 10.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.